StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
BDTXBlack Diamond Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$1.90▲ 0.53%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $108.9MShares out 57.3M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

5
  • 9.21After-hours26.09.22 06:45
    4Ownership#●●●

    Black Diamond Therapeutics, Inc.

    Insider Ali Behbahani reported a change in beneficial ownership of securities for Black Diamond Therapeutics, Inc. as of September 18, 2026. This filing is a Form 4 statement detailing the transaction involving the company's equity.…more

    $1.90+0.53%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.21After-hours26.09.22 06:30
    4Ownership

    Black Diamond Therapeutics, Inc.

    Executive Raman Prakash of Black Diamond Therapeutics reported a change in beneficial ownership of company securities as of September 18, 2026. This filing serves as a standard disclosure regarding the executive's stock holdings.…more

    $1.90+0.53%vs prev close
    View filingShare
  • 8.5After-hours26.08.06 05:04
    10-QEarnings

    Black Diamond Therapeutics, Inc.

    블랙 다이아몬드 테라퓨틱스는 2026년 6월 30일 기준 분기 보고서(10-Q)를 제출하였으며, 해당 시점의 발행 주식 수는 57,453,747주입니다. 회사는 실레버티닙(silevertinib) 및 BDTX-4933의 임상 개발과 서비에(Servier)와의 파트너십을 지속하며 운영 자금 확보 및 전략적 대안을 평가하고 있습니다.…more

    $1.90+0.53%vs prev close
    View filingShare

4 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.2After-hours26.09.03 05:01
    #●●●#●●●

    Black Diamond Therapeutics to Participate in H.C. Wainwright Investment Conference…more

    Black Diamond Therapeutics announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference for a fireside chat and investor meetings. This event is a standard corporate outreach activity and does not provide immediate material impact on the stock price.…more

    $1.90+0.53%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 8.5After-hours26.08.06 05:01

    ●●●●●●●● ●●●●● ●●●●●●

    블랙 다이아몬드 테라퓨틱스가 폐암 치료제 실레버티닙의 임상 2상에서 우수한 뇌 전이 억제 효과와 객관적 반응률을 확인했다. 회사는 2028년 하반기까지 운영 가능한 자금을 확보했으며, 연내 FDA와 핵심 개발 경로를 논의할 예정이다.…more

    $1.90+0.53%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →